Skip to content
AnalystLens

Exelixis Quarterly Report for Q3 Ended Sep 27, 2024

Filing Date
Filed October 29, 2024
Period End
September 27, 2024
Security
EXEL
One revenue dollarkept$0.22
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-Q filed October 29, 2024. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported third-quarter 2024 total revenues of $539.5 milliona, up from $471.9 million in the third quarter of 2023, with net income of $118.0 million, or $0.40 per diluted share, compared with net income of $1.0 million in the prior-year quarter.

Net product revenues were $478.1 millionb, driven by CABOMETYX, which generated $475.7 million in the quarter. For the nine months ended September 30, 2024, total revenues were $1.60 billion and net income was $381.4 million, aided by $299.9 million in license revenues, including a $150.0 million commercial milestone from Ipsen. Operating results also included a $51.7 million non-cash impairment charge related to Alameda leased facilities and $33.4 million in restructuring expenses under the 2024 Restructuring Plan.

The company ended the quarter with $1.7 billionc in cash, cash equivalents and marketable securities, unchanged in total from December 31, 2023, after repurchasing $461.6 million of common stock in the nine-month period. Management states that current resources should fund operations for at least 12 months. A new $500 million share repurchase authorization was approved in August 2024, with approximately $487.6 million remaining as of September 30, 2024.

Investors should note the ongoing generic competition risk to CABOMETYX. The company has settled litigation with Teva and Cipla with licenses beginning January 1, 2031, and a Delaware court ruled in October 2024 that generic entry under MSN's ANDA cannot occur before January 15, 2030.

Sun Pharmaceutical Industries also filed a Paragraph IV notice in September 2024, which the company is evaluating. Pipeline activity includes the sNDA for cabozantinib in pNET/epNET with a PDUFA target action date of April 3, 2025, and the phase 3 STELLAR-303 trial for zanzalintinib, with preliminary results expected in 2025.

Key Highlights

  1. Total revenues of $539.5 million in Q3 2024, up from $471.9 million in Q3 2023; net product revenues were $478.1 million.
  2. Net income of $118.0 million, or $0.40 per diluted share, in Q3 2024, versus $1.0 million in Q3 2023.
  3. Nine-month license revenues of $299.9 million, including a $150.0 million commercial milestone from Ipsen tied to $600.0 million in cumulative cabozantinib net sales.
  4. Research and development expenses fell to $222.6 million in Q3 2024 from $332.6 million a year earlier, while a $51.7 million impairment charge was recorded on Alameda leased facilities.
  5. Cash, cash equivalents and marketable securities totaled $1.7 billion at September 30, 2024, with $461.6 million used for stock repurchases in the nine months.
  6. A new $500 million stock repurchase program was authorized in August 2024, with approximately $487.6 million remaining as of September 30, 2024.
  7. Generic challenges to CABOMETYX continue; the Delaware court's October 2024 judgment bars approval of MSN's ANDA before January 15, 2030, and settlements with Teva and Cipla set licenses beginning January 1, 2031.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2025, Exelixis kept $0.22.

  1. Revenue$539.5M100.0%
  2. Cost of revenue−$17.3M3.2%
  3. Gross profit$522.2M96.8%
  4. Operating costs−$386.1M71.6%
  5. Operating income$136.1M25.2%
  6. Interest, other & tax−$18.1M3.4%
  7. Net income$118.0M21.9%
Computed from 10-QQ3 FY2025filed October 29, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2025 against Q3 FY2024

Line itemQ3 FY2025Q3 FY2024Change
Revenue$539.54M$471.92M+14.3%
Cost of Revenue$17.33M$18.77M−7.7%
Gross Profit$522.21M$453.15M+15.2%
R&D Expenses$222.57M$332.58M−33.1%
SG&A Expenses$111.80M$138.14M−19.1%
Operating Expenses$403.47M$489.50M−17.6%
Operating Income$136.07M-$17.58M+873.9%
Net Income$117.97M$1.04M+11232.7%
EPS (Basic)$0.41——
EPS (Diluted)$0.40——
Shares Outstanding (Basic)285.62M315.50M−9.5%
Shares Outstanding (Diluted)291.48M319.25M−8.7%

Frequently Asked Questions

  1. How did Exelixis perform financially in the third quarter of 2024?

    Total revenues were $539.5 million, up from $471.9 million a year earlier, and net income was $118.0 million, or $0.40 per diluted share, compared with $1.0 million, or $0.00 per share, in the third quarter of 2023. Net product revenues rose to $478.1 million from $426.5 million.

  2. What drove the large year-over-year change in license revenues?

    License revenues were $299.9 million for the nine months ended September 30, 2024, versus $133.4 million a year earlier. The increase was primarily due to a $150.0 million commercial milestone from Ipsen upon its achievement of $600.0 million in cumulative net sales of cabozantinib over four consecutive quarters, along with a $12.5 million regulatory milestone and other milestone and royalty revenues.

  3. What is the company's cash position and capital return activity?

    As of September 30, 2024, Exelixis had $1.7 billion in cash, cash equivalents and marketable securities, compared with $1.7 billion at December 31, 2023. During the nine months, it paid $461.6 million for repurchases of common stock, and it repurchased 0.5 million shares for $12.4 million under the August 2024 program.

  4. What are the main risks to CABOMETYX revenue?

    The filing describes proposed generic versions of CABOMETYX covered by ANDAs from MSN, Teva, Cipla and Sun. The company states that approval and launch of any generic could significantly decrease U.S. CABOMETYX revenues. In October 2024, the Delaware District Court set January 15, 2030 as the earliest effective date of any FDA approval of MSN's ANDA, and the Teva and Cipla settlements provide for licenses beginning January 1, 2031.

  5. What upcoming pipeline and regulatory events does the filing identify?

    The FDA accepted an sNDA for cabozantinib in previously treated, locally advanced/unresectable or metastatic pNET and epNET, with a PDUFA target action date of April 3, 2025. Preliminary results from the phase 3 STELLAR-303 trial of zanzalintinib in colorectal cancer are expected in 2025, and the company intends to submit an sNDA for CONTACT-02 in the fourth quarter of 2024.